PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/777,526
Filing Date	February 6, 2001
First Named Inventor	Agrawal et al
Art Unit	1635
Examiner Name	Terra C Gibbs
Attorney Docket Number	HYZ-030CPCN3 47508.5 18

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2004-0033980	02-19-2004	Agrawal, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	2/24/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/777,526
Filing Date	February 6, 2001
First Named Inventor	Agrawal, et al.
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	HYZ-030CPCN3.47508.5

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LL		US- 6,608,035	08-19-03	Agrawal, et al.	
LL		US- 6,645,943	11-11-03	Agrawal, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	2/24/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Subst. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number	Application Number
HYZ-030CPCN3	09/777,526
Applicant	
Agrawal et al.	
Filing Date	**Group Art Unit**
February 6, 2001	1635

Sheet 1 OF 4

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,309,404	1/5/1982	DeNeale et al.	424	21	
	4,309,406	1/5/1982	Guley et al.	424	21	
	4,556,552	12/3/1985	Porter et al.	424	32	
	4,704,295	11/3/1987	Porter et al.	427	3	
	5,220,007	6/15/1993	Pederson et al.	536	23.1	
	5,149,797	9/22/1992	Pederson et al.	536	23.1	
	5,220,007	12/21/1993	Cho-Chung	424	450	
	5,248,670	9/28/1993	Draper et al.	514	44	
	5,271,941	12/21/1993	Cho-Chung	424	450	
	5,403,709	10/6/1992	Agrawal et al.	435	6	
	5,442,049	8/15/1995	Anderson et al.	536	24.5	
	5,470,967	11/28/1995	Huie et al.	536	24.3	
	5,514,577	5/7/1996	Draper et al	435	238	
	5,578,716	12/1/1993	Szyf et al.	536	24.5	
	5,612,212	11/12/1993	Gewirtz	435	456	
	6,143,881	11/7/2000	Metelev et al.	536	24.5	
	5,652,355	7/29/1997	Metelev et al.	536	24.5	
	5,969,117	10/19/1999	Agrawal	536	22.1	

DUPLICATES

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	94/02498	2/3/1994	WO	C07H 21	00		X
	94/15619	7/21/1994	WO	A61K 31	70		X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	A1	Agrawal, Sudhir, "Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups." *Methods Mol Biol.*, Vol. 26, pp. 93-120 (1994)
	A2	Agrawal et al., "Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues." *Proc Natl Acad Sci U S A.*, Vol. 86, No. 20, pp. 7790-4 (1989)
	A3	Agrawal, Antisense Therapeutics, (Sudhir Agrawal, ed.) , Page V (1996)

EXAMINER	DATE CONSIDERED
Lynn Feld	3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number	Application Number
HYZ-030CPCN3	09/777,526

Applicant	
Agrawal et al.	

Filing Date	Group Art Unit
February 6, 2001	1635

Sheet 2 OF 4

RECEIVED
MAY 23 2001
TECH CENTER 1600/290

OIPE
MAY 21 2001
PATENT & TRADEMARK OFFICE

	A4	Agrawal et al., "Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides." *Proc Natl Acad Sci U S A.*, Vol. 87, No. 4, pp. 1401-5 (1990)
	B1	Agrawal et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice." *Proc Natl Acad Sci U S A.*, Vol. 88, No. 17, pp. 7595-9 (1991)
	B2	Agrawal et al., "Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration." *Biochem Pharmacol.*, Vol. 50, No. 4, pp. 571-6 (1995)
	B3	Agrawal et al., "Antisense oligonucleotides as antiviral agents." *Trends in Biotechnol.*, Vol. 10, pp. 152-158 (1992)
	B4	Agrawal et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus." *Proc. Natl. Acad. Sci.* (USA), Vol. 85, pp. 7079-7083 (1988)
	B5	Agrawal, S., "History of Antisense Oligonucleotides" in Antisense Therapeutics (Sudhir Agrawal ed.), Human Press, Totowa, New Jersey (1996)
	B6	Craig et al., *Exp. Opin. Ther. Patents* 7:1175-1182 (1997)
	B7	Bayever et al., "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial." *Antisense Res Dev.* Vol. 3, No. 4, pp. 383-90 (1993)
	B8	Boutorine et al, *Biochimie* 76: 23-32 (1994)
	B9	Ceruzzi et al., *Nucleosides and Nucleotides* 8 (5&6): 815-8 (1989)
	B10	Egli et al. (10/8-9/98) Antisense 98, Targeting the Molecular Basis of Disease, pp. 37
	B11	Furdon et al., "RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds." *Nucleic Acids Res.*, Vol. 17, No. 22, pp. 9193-204 (1989)
	B12	Galderisi et al., "Antisense oligonucleotides as therapeutic agents." *J. Cell. Physiol.*, Vol. 181, pp. 251-57 (1999)
	B13	Hughes et al., "Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs." *Pharm Res.*, Vol. 6, pp. 817-24. (1995)
	B14	Isis Pharmaceuticals –Press Release 060500, June 5 (2000)
	B15	Isis Pharmaceuticals, Inc., *Antisense 97: Targeting the Molecular Basis of Disease*, Nature Biotechnology Conference, May 1-2 1997
	B16	International Business Communications, *IBC,'s Fourth Annual International Sysmposium on Oligonucleotides and Gene Therapy-Based Antisense Therapeutics with New Applications for Genomics*, February 6-7 1997
	B17	International Business Communications, *IBC,'s Sixth Annual International Conference on Oligo-Therapeutics, Molecular Tools and Novel Therapeutic Strategies*, May 1999

EXAMINER	DATE CONSIDERED
	3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. For, PTO-1449	Docket Numb	Application Number
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)	HYZ-030CPCN3	09/777,526
	Applicant: Agrawal et al.	
3 OF 4	Filing Date: February 6, 2001	Group Art Unit: 1635

RECEIVED
MAY 23 2001
TECH CENTER 1600/2900

	B17	Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H." *FEBS Lett.*, Vol. 215, No. 2, pp. 327-30 (1987)
	B18	Inoue et al., *FEBS Lett.*, Vol. 215, pp. 237-250 (1987)
	B19	Iversen, "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue." *Anticancer Drug Des.*, Vol. 6, No. 6, pp. 531-8 (1991)
	C1	Iversen, "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion." *Antisense Res Dev.*, Vol. 4, No. 1, pp. 43-52 (1994)
	C2	Kawasaki et al., "Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets." *J Med Chem.*, Vol. 36, No.7, pp. 831-41 (1993)
	C3	Levin (10/8-9/98) Antisense 98, Targeting the Molecular Basis of Disease, pp. 25
	C4	Martin, P . *Helvetica Chimica Acta*, 78: 486-504 (1995)
	C5	Metelev et al, *Bioorganic & Medicinal Chemistry Letters*, 4: 2929-2934 (1994)
	C6	Milligan et al., "Current concepts in antisense drug design." *J Med Chem.*, Vol. 36, No. 14, pp. 1923-37 (1993)
	C7	Orr, (Reported By) Antisense 98: "Targeting the Molecular Basis of Disease (Part III)" Organized by Nature Biology, London, UK (1988)
	C8	Quartin et al., "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates." *Nucleic Acids Res.*, Vol. 17, No. 18, pp. 7253-62 (1989)
	C9	Rapaport et al., "Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistant Plasmodium falciparum." *Proc Natl Acad Sci U S A.*, Vol. 89, No. 18, pp. 8577-80 (1992)
	C10	Sands, "Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate." *Mol Pharmacol.*, Vol. 45, No. 5, pp. 932-43 (1994)
	C11	Shibahara et al., "Site-directed cleavage of RNA." *Nucleic Acids Res.*, Vol. 15, No. 11, pp. 4403-15 (1987)
	C12	Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives." *Nucleic Acids Res.*, Vol. 17, No. 1, pp. 239-52 (1989)
	C13	Shibahara et al., *Nucleic Acids Res.*, Vol. 15, pp. 4403-4415 (1987)
	C14	Sonveaux, "*Protecting Groups in Oligonucleotide Synthesis*", *in Methods in Molecular Biology* (Agrawal ed.) 26:1-71 (1994)
	C15	Stein et al., "Antisense oligonucleotides as therapeutic agents--is the bullet really magical?" *Science*, Vol. 261, No. 5124, pp. 1004-12 (1993)
	C16	Takashima et al., "Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity." *Proc Natl Acad Sci U S A.*, Vol. 90, No. 16, pp. 7789-93 (1993)
	C17	Tidd et al., "Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups." *Br J Cancer.*, Vol. 60, No. 3, pp. 343-50 (1989)

EXAMINER	DATE CONSIDERED
	3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subst. For, PTO-1449	Docket Numb[redacted]	Application Number
INFORMATION DISCLOSURE IN AN APPLICATION	HYZ-030CPCN3	09/777,526
(Use several sheets if necessary)	Applicant: Agrawal et al.	
Sheet: 4 OF 4	Filing Date: February 6, 2001	Group Art Unit: 1635

	C18	Tortora et al., "Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production." *Clin Cancer Res.* Vol. 6, No. 6, pp. 2506-12 (2000)
	C19	Tseng et al., "Antisense oligonucleotide technology in the development of cancer therapeutics." *Cancer Gene Ther.*;Vol. 1, pp. 65-71 (1994)
	C20	Uhlmann et al., "Antisense Oligonculeotides: A New Therapeutic Principle" *Chem. Rev.* Vol. 90, pp. 543-584 (1990)
	D1	Wang et al., "Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration." *Proc Natl Acad Sci U S A.*, Vol. 96, No. 24, pp. 13989-94 (1999)
	D2	Wickstrom, E., "Oligodeoxynucleotide stability in subcellular extracts and culture media." *J Biochem Biophys Methods.*, Vol. 13, No. 2, pp. 97-102. (1986)
	D3	Wickstrom, E., "Strategies for administering targeted therapeutic oligodeoxynucleotides." *Trends Biotechnol.*, Vol. 10, No. 8, pp. 281-7(1992)
	D4	Zamecnic, P., "History of Antisense Oligonucleotides" in Antisense Therapeutics (Sudhir Agrawal ed.), Human Press, Totowa, New Jersey (1996) pp. 1-11.
	D5	Zhao et al., *Antisense Res. and Dev.* 3: 53-66 (1993)
	D6	Zon, *Pharm.Res* 5(9): 539-49 (1988)
	D7	Zendegui et al., "In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides." *Nucleic Acids Res.*, Vol. 20, No. 2, pp. 307-14 (1992)

EXAMINER	DATE CONSIDERED
[signature]	3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609. Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.